Synthetic anti-BR3 antibodies that mimic BAFF binding and target both human and murine B cells

Blood

Volumn 108, Issue 9, 2006, Pages 3103-3111

  Lee, Chingwei V ^a   Hymowitz, Sarah G ^a   Wallweber, Heidi J ^a   Gordon, Nathaniel C ^a   Billeci, Karen L ^a   Tsai, Siao Ping ^a   Compaan, Deanne M ^a   Yin, JianPing ^a   Gong, Qian ^a   Kelley, Robert F ^a   DeForge, Laura E ^a   Martin, Flavius ^a   Starovasnik, Melissa A ^a   Fuh, Germaine ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; B LYMPHOCYTE RECEPTOR; BR3 ANTIBODY; CB1 ANTIBODY; EPITOPE; PROTEIN ANTIBODY; PROTEIN BAFF; PROTEIN BR3; RECOMBINANT ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; BINDING AFFINITY; BINDING SITE; CELL POPULATION; CELL PROLIFERATION; CONTROLLED STUDY; CROSS REACTION; CRYSTALLOGRAPHY; EXTRACELLULAR SPACE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; TARGET CELL;

EID: 33751198274     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-03-011031     Document Type: Article

References (49)

1. Thompson JS, Bixler SA, Qian F, et al. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science. 2001;293:2108-2111.
2. Yan M, Brady JR, Chan B, et al. Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency. Curr Biol. 2001;11:1547-1552.
3. Ng LG, Sutherland APR, Newton R, et al. B cellactivating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J Immunol. 2004;173:807-817.
4. Novak AJ, Grote DM, Stenson M, et al. Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. Blood. 2004;104:2247-2253.
5. Schneider P. The role of APRIL and BAFF in lymphocyte activation. Curr Opin Immunol. 2005;17:282-289.
6. Mackay F, Browning JL. BAFF: a fundamental survival factor for B cells. Nature Rev Immunol. 2002;2:465-475.
7. Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum. 2001;44:1313-1319.
8. Groom J, Kalled SL, Cutler AH, et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome. J Clin Invest. 2002;109:59-68.
9. Zhang J, Roschke V, Baker KP, et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol. 2001;166:6-10.
10. Kayagaki N, Yan M, Seshasayee D, et al. BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-κB2. Immunity. 2002;17:515-524.
11. Gross JA, Dillon SR, Mudri S, et al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease: impaired B cell maturation in mice lacking BLyS. Immunity. 2001;15:289-302.
12. Wang H, Marsters SA, Baker T, et al. TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice. Nat Immunol. 2001;2:632-637.
13. Baker KP, Edwards BM, Main SH, et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 2003;48:3253-3265.
14. Martin F, Chan AC. B cell immunobiology in disease: evolving concepts from the clinic. Annu Rev Immunol. 2006;24:467-496.
15. Vugmeyster Y, Seshasayee D, Chang W, et al. A soluble BAFF antagonist, BR3-Fc, decreases peripheral blood B cells and lymphoid tissue marginal zone and follicular B cells in cynomolgus monkeys. Am J Pathol. 2006;168:476-489.
16. Shulga-Morskaya S, Dobles M, Walsh ME, et al. B cell-activating factor belonging to the TNF family acts through separate receptors to support B cell survival and T cell-independent antibody formation. J Immunol. 2004;173:2331-2341.
17. Seshasayee D, Valdez P, Yan M, Dixit VM, Tumas D, Grewal IS. Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity. 2003;18:279-288.
18. Castigli E, Wilson S, Scott S, et al. TACI and BAFF-R mediate isotype switching in B cells. J Exp Med. 2005;201:35-39.
19. Salzer U, Chapel H, Webster A, et al. Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat Genet. 2005;37:820-828.
20. O'Connor BP, Raman VS, Erickson LD, et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med. 2004;199:91-97.
21. Menegazzi R, Cramer R, Patriarca P, Scheurich P, Dri P. Evidence that tumor necrosis factor alpha (TNF) induced activation of neutrophil respiratory burst on biologic surface is mediated by the p55 TNF receptor. Blood. 1994;84:287-293.
22. Gonzalez-Cuadrado S, Lopez-Armada MJ, Gomez-Guerrero C, et al. Anti-Fas antibodies induce cytolysis and apoptosis in cultured human mesangial cells. Kidney Int. 1996;49:1064-1070.
23. Sun Y, Chen HM, Subudhi SK, et al. Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease. Nat Med. 2002;8:1256-1258.
24. Ichikawa K, Liu W, Zhao L, et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatic cytotoxicity. Nat Med. 2001;7:954-960.
25. Schwabe RF, Hess S, Johnson JP, Engelmann H. Modulation of soluble CD40 ligand bioactivity with anti-CD40 antibodies. Hybridoma. 1997;16:217-226.
26. Carnemolla B, Neri D, Castellani P, et al. Phage antibodies with pan-species recognition of the oncofoetal angiogenesis marker fibronectin ED-B domain. Int J Cancer. 1996;68:397-405.
27. Lee CV, Liang W-c, Dennis MS, Eigenbrot C, Sidhu S, Fuh G. High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold. J Mol Biol. 2004;340:1073-1093.
28. Fuh G, Wu P, Liang W-C, et al. Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin-Fab. J Biol Chem. 2006;281:6625-6631.
29. Gallop M, Barrett R, Dower W, Fodor S, Gordon E. Applications of combinatorial technologies to drug discovery, 1: background and peptide combinatorial libraries. J Med Chem. 1994;37:1233-1251.
30. Sidhu SS, Li B, Fellouse F, Eigenbrot C, Fuh G. Phage-displayed antibody libraries of synthetic heavy chain complementarity determining regions. J Mol Biol. 2004;338:299-310.
31. Gordon NC, Pan B, Hymowitz SG, et al. BAFF/BLyS receptor 3 comprises a minimal TNF receptor-like module that encodes a highly focused ligand-binding site. Biochemistry. 2003;42:5997-5983.
32. Weiss GA, Watanabe CK, Zhong A, Goddard A, Sidhu SS. Rapid mapping of protein functional epitopes by combinatorial alanine scanning. Proc Natl Acad Sci U S A. 2000;97:8950-8954.
33. Pelletier M, Thompson JS, Qian F, et al. Comparison of soluble decoy IgG fusion proteins of BAFF-R and BCMA as antagonists for BAFF. J Biol Chem. 2003;278:33127-33133.
34. Laskowski RA, MacArthur MW, Moss DS, Thornton JM. PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Crystallogr. 1993;26:283-291.
35. Kim HM, Yu KS, Lee ME, et al. Crystal structure of the BAFF-BAFF-R complex and its implications for receptor activation. Nat Struct Biol. 2003;10:342-348.
36. Lee CV, Sidhu SS, Fuh G. Bivalent antibody phage display mimics natural immunoglobulin. J Immunol Methods. 2004;284:119-132.
37. Vajdos FF, Adams CW, Breece TN, Presta LG, de Vos AM, Sidhu SS. Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis. J Mol Biol. 2002;320:415-428.
38. Shield RL, Namenuk AK, Hong K, et al. High resolution mapping of the binding site on human IgG1 for FcgRI, FcgRII, FcgRIII, and FcRn and design of IgG1 variants with improved binding to the FcgR. J Biol Chem. 2001;276:6591-6604.
39. Yang W, Green K, Ping-sweeney S, Briones A, Burton D, Barbas III C. CDR walking mutagenesis for the affinity maturation for a potent human anti-HIV-1 antibody into the picomolar range. J Mol Biol. 1995;254:392-403.
40. Dennis MS, Roberge M, Quan C, Lazarus RA. Selection and characterization of a new class of peptide exosite inhibitors of coagulation factor VIIa. Biochemistry. 2001;40:9513-9521.
41. Wrighton NC, Farrell FX, Chang R, et al. Small peptides as potent mimetics of the protein hormone erythropoietin. Science. 1996;273:458-463.
42. Hymowitz SG, Patel DR, Wallweber HJA, et al. Structures of APRIL-receptor complexes: Like BCMA, TACI employs only a single cysteine-rich domain for high-affinity ligand binding. J Biol Chem. 2005;280:7218-7227.
43. Zhang G. Tumor necrosis factor family ligand-receptor binding. Curr Opin Struct Biol. 2004;14:154-160.
44. Liu Y, Hong X, Kappler J, et al. Ligand-receptor binding revealed by the TNF family member TALL-1. Nature. 2003;423:49-56.
45. Clackson T, Wells JA. A hot spot of binding energy in a hormone-receptor interface. Science. 1995;267:383-386.
46. Moore PA, Belvedere O, Orr A, et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science. 1999;285:260-263.
47. Li W, Keeble AH, Giffard C, James R, Moore GR, Kleanthous C. Highly discriminating protein-protein interaction specificities in the context of a conserved binding energy hotspot. J Mol Biol. 2004;337:743-759.
48. Gong Q, Ou Q, Ye S, et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol. 2005;174:817-826.
49. Martin F, Chan AC. Pathogenic roles of B cells in human autoimmunity: insights from the clinic. Immunity. 2004;20:517-527.